Cell Biotech Co., Ltd.

KOSDAQ:A049960 Stock Report

Market Cap: ₩97.0b

Cell Biotech Past Earnings Performance

Past criteria checks 5/6

Cell Biotech has been growing earnings at an average annual rate of 3.8%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 3.6% per year. Cell Biotech's return on equity is 9.4%, and it has net margins of 20.9%.

Key information

3.8%

Earnings growth rate

5.5%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate3.6%
Return on equity9.4%
Net Margin20.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings

Aug 24
Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings

Recent updates

Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings

Aug 24
Shareholders Will Be Pleased With The Quality of Cell Biotech's (KOSDAQ:049960) Earnings

Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio

May 05
Factors Income Investors Should Consider Before Adding Cell Biotech Co., Ltd. (KOSDAQ:049960) To Their Portfolio

Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 18
Is Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Recent Price Movement Underpinned By Its Weak Fundamentals?

A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns

Feb 25
A Look At Cell Biotech's (KOSDAQ:049960) Share Price Returns

Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend

Feb 04
Key Things To Watch Out For If You Are After Cell Biotech Co., Ltd.'s (KOSDAQ:049960) 3.2% Dividend

Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?

Jan 14
Is Cell Biotech Co., Ltd. (KOSDAQ:049960) Popular Amongst Insiders?

Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend

Dec 24
Don't Race Out To Buy Cell Biotech Co., Ltd. (KOSDAQ:049960) Just Because It's Going Ex-Dividend

Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Dec 13
Cell Biotech Co., Ltd.'s (KOSDAQ:049960) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years

Nov 18
Reflecting on Cell Biotech's (KOSDAQ:049960) Share Price Returns Over The Last Five Years

Revenue & Expenses Breakdown

How Cell Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A049960 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2452,60010,97422,3713,971
30 Jun 2454,09712,96623,9284,070
31 Mar 2453,9806,70829,3984,034
31 Dec 2353,7876,30429,8453,725
30 Sep 2352,75116630,9413,544
30 Jun 2351,5092,73629,8473,457
31 Mar 2351,2728,12826,5953,510
31 Dec 2250,5268,28125,2783,559
30 Sep 2248,75414,64223,4073,712
30 Jun 2249,08112,99722,9323,627
31 Mar 2248,32810,63222,2843,677
31 Dec 2146,87310,38321,9873,500
30 Sep 2145,7616,03222,5123,181
30 Jun 2144,1963,27023,5763,207
31 Mar 2144,1562,94224,1653,243
31 Dec 2045,5823,18924,6413,329
30 Sep 2046,9905,90024,7873,800
30 Jun 2046,3336,47224,3453,856
31 Mar 2046,5828,01723,8263,673
31 Dec 1945,9607,23123,6973,704
30 Sep 1949,34611,37922,7963,421
30 Jun 1953,47313,58522,5183,419
31 Mar 1958,13616,54422,4543,362
31 Dec 1862,54419,38422,4353,433
30 Sep 1860,32416,52522,8303,369
30 Jun 1861,30117,86522,9703,271
31 Mar 1862,29519,80221,9163,156
31 Dec 1761,05718,19821,4972,886
30 Sep 1762,70620,75622,2422,908
30 Jun 1758,93718,58120,8852,880
31 Mar 1757,15017,07119,6182,945
31 Dec 1658,27618,49920,0972,918
30 Sep 1655,04817,71916,9413,047
30 Jun 1657,41821,70516,4643,064
31 Mar 1655,23020,60317,1622,838
31 Dec 1549,50517,50515,6022,844
30 Sep 1549,29116,58217,2592,386
30 Jun 1544,99712,47416,2742,303
31 Mar 1541,35010,32914,3212,257
31 Dec 1440,76810,40314,0762,057
30 Sep 1439,1119,92912,3432,027
30 Jun 1436,5608,87911,8381,775
31 Mar 1434,8238,99811,1311,718
31 Dec 1331,5987,80010,2331,916

Quality Earnings: A049960 has high quality earnings.

Growing Profit Margin: A049960's current net profit margins (20.9%) are higher than last year (0.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A049960's earnings have grown by 3.8% per year over the past 5 years.

Accelerating Growth: A049960's earnings growth over the past year (6518%) exceeds its 5-year average (3.8% per year).

Earnings vs Industry: A049960 earnings growth over the past year (6518%) exceeded the Biotechs industry 7.9%.

Return on Equity

High ROE: A049960's Return on Equity (9.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 09:39
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cell Biotech Co., Ltd. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Young Ok KimDAOL Investment & Securities Co., Ltd.
Hyuk Jin YoonEugene Investment & Securities Co Ltd.
Han ParkHyundai Motor Securities Co. Ltd.